{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:59:15Z","timestamp":1761238755518,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472441"],"award-info":[{"award-number":["81472441"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The prognostic value and optimal resection outcome related factors of the secondary cytoreduction surgery (SCR) in Platinum-sensitive recurrent ovarian cancer (PSOC) patients were still in doubt. The present retrospective study aims to determine the relationship between the objective response of secondary neo-adjuvant chemotherapy (SNAC) and the resection outcome of SCR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were reviewed from 142 type II PSOCs who underwent SCR in Jiangsu Institute of Cancer Research between 1996 and 2016. Among them, 55 cases received preliminary Platinum based SNAC before SCR. Logistic regression analysis was used to explore optimal SCR related factors. Cox proportional hazards model and log-rank test were used to assess the associations between the survival durations and covariates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Optimal initial CRS (<jats:italic>p<\/jats:italic>\u2009=\u20090.02), disappearance of ascites after SNAC (<jats:italic>p<\/jats:italic>\u2009=\u20090.04) recurrent status (<jats:italic>p<\/jats:italic>\u00a0=\u20090.02) and longer Platinum-free interval (<jats:italic>p<\/jats:italic>\u2009=\u20090.01) were the independent indicators of optimal SCR. Optimal SCR was associated with time to progression (TTP) but not overall survival (OS) (<jats:italic>p<\/jats:italic>\u00a0=\u20090.04 and<jats:italic>p<\/jats:italic>\u2009=\u20090.41). The TTP and OS of PSOCs underwent SNAC were similar to those patients underwent SCR (<jats:italic>p<\/jats:italic>\u2009=\u20090.71, and<jats:italic>p<\/jats:italic>\u2009=\u20090.77, respectively) directly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>SNAC might be another choice for PSOCs were not suitable for directly SCR. Optimal SCR had survival benefit in PSOCs whenever underwent SNAC or not.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13048-020-00673-0","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T15:42:28Z","timestamp":1592322148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial"],"prefix":"10.1186","volume":"13","author":[{"given":"Hongyuan","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianzhong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2400-4749","authenticated-orcid":false,"given":"Xiaoxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"673_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin"},{"key":"673_CR2","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519\u201329.","journal-title":"N Engl J Med"},{"key":"673_CR3","doi-asserted-by":"crossref","unstructured":"Du Bois A, Vergote I, Ferron G, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20. Am Soc Clin Oncol. 2017.","DOI":"10.1200\/JCO.2017.35.15_suppl.5501"},{"key":"673_CR4","doi-asserted-by":"crossref","unstructured":"Coleman RL, Enserro D, Spirtos N, et al. A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): a NRG oncology\/gynecologic oncology group (GOG) study. Am Soc Clin Oncol. 2018.","DOI":"10.1200\/JCO.2018.36.15_suppl.5501"},{"key":"673_CR5","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Spirtos NM, Enserro D, et al. Secondary surgical Cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381:1929\u201339.","journal-title":"N Engl J Med"},{"key":"673_CR6","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","volume":"18","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology\/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:779\u201391.","journal-title":"Lancet Oncol"},{"key":"673_CR7","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1245\/s10434-006-9273-8","volume":"14","author":"P Benedetti Panici","year":"2007","unstructured":"Benedetti Panici P, De Vivo A, Bellati F, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol. 2007;14:1136\u201342.","journal-title":"Ann Surg Oncol"},{"key":"673_CR8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jso.21470","volume":"101","author":"JY Park","year":"2010","unstructured":"Park JY, Eom JM, Kim DY, et al. Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer. J Surg Oncol. 2010;101:418\u201324.","journal-title":"J Surg Oncol"},{"key":"673_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/j.1600-0412.1998.770220.x","volume":"77","author":"F Landoni","year":"1998","unstructured":"Landoni F, Pellegrino A, Cormio G, et al. Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy. Acta Obstet Gynecol Scand. 1998;77:233\u20137.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"673_CR10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/jso.23094","volume":"106","author":"N Boran","year":"2012","unstructured":"Boran N, Hizli D, Yilmaz S, et al. Secondary cytoreductive surgery outcomes of selected patients with paclitaxel\/platinum sensitive recurrent epithelial ovarian cancer. J Surg Oncol. 2012;106:369\u201375.","journal-title":"J Surg Oncol"},{"key":"673_CR11","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/cncr.21845","volume":"106","author":"DS Chi","year":"2006","unstructured":"Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106:1933\u20139.","journal-title":"Cancer"},{"key":"673_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","volume":"112","author":"RE Bristow","year":"2009","unstructured":"Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:265\u201374.","journal-title":"Gynecol Oncol"},{"key":"673_CR13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11912-012-0260-x","volume":"14","author":"P Harter","year":"2012","unstructured":"Harter P, Heitz F, du Bois A. Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep. 2012;14:539\u201343.","journal-title":"Curr Oncol Rep"},{"key":"673_CR14","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/jso.21652","volume":"102","author":"J Sehouli","year":"2010","unstructured":"Sehouli J, Richter R, Braicu EI, et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol. 2010;102:656\u201362.","journal-title":"J Surg Oncol"},{"key":"673_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ygyno.2016.04.537","volume":"142","author":"DH Suh","year":"2016","unstructured":"Suh DH, Kim HS, Chang SJ, et al. Surgical management of recurrent ovarian cancer. Gynecol Oncol. 2016;142:357\u201367.","journal-title":"Gynecol Oncol"},{"key":"673_CR16","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","volume":"13","author":"P Harter","year":"2006","unstructured":"Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13:1702\u201310.","journal-title":"Ann Surg Oncol"},{"key":"673_CR17","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1245\/s10434-009-0357-0","volume":"16","author":"P Harter","year":"2009","unstructured":"Harter P, Hahmann M, Lueck HJ, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:1324\u201330.","journal-title":"Ann Surg Oncol"},{"key":"673_CR18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","volume":"19","author":"WJ Tian","year":"2012","unstructured":"Tian WJ, Chi DS, Sehouli J, et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol. 2012;19:597\u2013604.","journal-title":"Ann Surg Oncol"},{"key":"673_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1757-2215-6-14","volume":"6","author":"F Wang","year":"2013","unstructured":"Wang F, Ye Y, Xu X, et al. CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. J Ovarian Res. 2013;6:14.","journal-title":"J Ovarian Res"},{"key":"673_CR20","first-page":"619","volume":"17","author":"DM O'Malley","year":"2019","unstructured":"O'Malley DM. New therapies for ovarian cancer. J Natl Compr Cancer Netw. 2019;17:619\u201321.","journal-title":"J Natl Compr Cancer Netw"},{"key":"673_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ygyno.2010.10.008","volume":"120","author":"E Burton","year":"2011","unstructured":"Burton E, Chase D, Yamamoto M, et al. Surgical management of recurrent ovarian cancer: the advantage of collaborative surgical management and a multidisciplinary approach. Gynecol Oncol. 2011;120:29\u201332.","journal-title":"Gynecol Oncol"},{"key":"673_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"673_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"673_CR24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","volume":"21","author":"M Friedlander","year":"2011","unstructured":"Friedlander M, Trimble E, Tinker A, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21:771\u20135.","journal-title":"Int J Gynecol Cancer"},{"key":"673_CR25","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/annonc\/mdw663","volume":"28","author":"M Wilson","year":"2016","unstructured":"Wilson M, Pujade-Lauraine E, Aoki D, et al. Fifth ovarian Cancer consensus conference of the gynecologic cancer InterGroup: recurrent disease. Ann Oncol. 2016;28:727\u201332.","journal-title":"Ann Oncol"},{"key":"673_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","volume":"139","author":"C Aghajanian","year":"2015","unstructured":"Aghajanian C, Goff B, Nycum LR, et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015;139:10\u20136.","journal-title":"Gynecol Oncol"},{"key":"673_CR27","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274\u201384.","journal-title":"Lancet Oncol"},{"key":"673_CR28","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S1470-2045(18)30343-7","volume":"19","author":"M Friedlander","year":"2018","unstructured":"Friedlander M, Gebski V, Gibbs E, et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol. 2018;19:1126\u201334.","journal-title":"Lancet Oncol"},{"key":"673_CR29","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S1470-2045(18)30333-4","volume":"19","author":"AM Oza","year":"2018","unstructured":"Oza AM, Matulonis UA, Malander S, et al. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2018;19:1117\u201325.","journal-title":"Lancet Oncol"},{"key":"673_CR30","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1200\/JCO.18.02238","volume":"37","author":"JM Del Campo","year":"2019","unstructured":"Del Campo JM, Matulonis UA, Malander S, et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial. J Clin Oncol. 2019;37:2968\u201373.","journal-title":"J Clin Oncol"},{"key":"673_CR31","first-page":"JCO1900917","volume":"1","author":"UA Matulonis","year":"2019","unstructured":"Matulonis UA, Walder L, Nottrup TJ, et al. Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16\/NOVA trial. J Clin Oncol. 2019;1:JCO1900917.","journal-title":"J Clin Oncol"},{"key":"673_CR32","first-page":"CD008765","volume":"1","author":"T Al Rawahi","year":"2013","unstructured":"Al Rawahi T, Lopes AD, Bristow RE, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;1:CD008765.","journal-title":"Cochrane Database Syst Rev"},{"key":"673_CR33","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/cncr.20106","volume":"100","author":"RY Zang","year":"2004","unstructured":"Zang RY, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer. 2004;100:1152\u201361.","journal-title":"Cancer"},{"key":"673_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/1096-9098(200009)75:1<24::AID-JSO5>3.0.CO;2-L","volume":"75","author":"RY Zang","year":"2000","unstructured":"Zang RY, Zhang ZY, Li ZT, et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol. 2000;75:24\u201330.","journal-title":"J Surg Oncol"},{"key":"673_CR35","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.ejso.2009.03.010","volume":"35","author":"X Cheng","year":"2009","unstructured":"Cheng X, Jiang R, Li ZT, et al. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC). Eur J Surg Oncol. 2009;35:1105\u20138.","journal-title":"Eur J Surg Oncol"},{"key":"673_CR36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ygyno.2004.11.057","volume":"97","author":"M Gungor","year":"2005","unstructured":"Gungor M, Ortac F, Arvas M, et al. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol. 2005;97:74\u20139.","journal-title":"Gynecol Oncol"},{"key":"673_CR37","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/sj.bjc.6602466","volume":"92","author":"T Onda","year":"2005","unstructured":"Onda T, Yoshikawa H, Yasugi T, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer. 2005;92:1026\u201332.","journal-title":"Br J Cancer"},{"key":"673_CR38","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1006\/gyno.2001.6404","volume":"83","author":"C Scarabelli","year":"2001","unstructured":"Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2001;83:504\u201312.","journal-title":"Gynecol Oncol"},{"key":"673_CR39","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X","volume":"88","author":"SM Eisenkop","year":"2000","unstructured":"Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88:144\u201353.","journal-title":"Cancer"},{"key":"673_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/IGC.0000000000000841","volume":"27","author":"R Kruitwagen","year":"2017","unstructured":"Kruitwagen R, Zusterzeel P, Van TG, et al. Correspondence: premature stop of the SOCceR trial, a multicenter randomized controlled trial on secondary Cytoreductive surgery: Netherlands trial register number: NTR3337. Int J Gynecol Cancer. 2017;27:2\u20132.","journal-title":"Int J Gynecol Cancer"},{"key":"673_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1756-9966-32-61","volume":"32","author":"X Xu","year":"2013","unstructured":"Xu X, Chen X, Dai Z, et al. Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer. J Exp Clin Cancer Res. 2013;32:61.","journal-title":"J Exp Clin Cancer Res"},{"key":"673_CR42","first-page":"189","volume":"61","author":"JS Berek","year":"1983","unstructured":"Berek JS, Hacker NF, Lagasse LD, et al. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol. 1983;61:189\u201393.","journal-title":"Obstet Gynecol"},{"key":"673_CR43","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/cncr.22447","volume":"109","author":"R Salani","year":"2007","unstructured":"Salani R, Santillan A, Zahurak ML, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007;109:685\u201391.","journal-title":"Cancer"},{"key":"673_CR44","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ygyno.2007.04.006","volume":"106","author":"SJ Tebes","year":"2007","unstructured":"Tebes SJ, Sayer RA, Palmer JM, et al. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2007;106:482\u20137.","journal-title":"Gynecol Oncol"},{"key":"673_CR45","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ygyno.2004.09.018","volume":"95","author":"AR Munkarah","year":"2004","unstructured":"Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol. 2004;95:273\u201380.","journal-title":"Gynecol Oncol"},{"key":"673_CR46","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1006\/gyno.2001.6143","volume":"81","author":"A Munkarah","year":"2001","unstructured":"Munkarah A, Levenback C, Wolf JK, et al. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol. 2001;81:237\u201341.","journal-title":"Gynecol Oncol"},{"key":"673_CR47","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/bjc.2011.328","volume":"105","author":"RY Zang","year":"2011","unstructured":"Zang RY, Harter P, Chi DS, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011;105:890\u20136.","journal-title":"Br J Cancer"},{"key":"673_CR48","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3802\/jgo.2009.20.3.198","volume":"20","author":"K Kim","year":"2009","unstructured":"Kim K, Ryu SY. Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. J Gynecol Oncol. 2009;20:198.","journal-title":"J Gynecol Oncol"},{"key":"673_CR49","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3802\/jgo.2009.20.2.101","volume":"20","author":"J Bae","year":"2009","unstructured":"Bae J, Lim MC, Choi JH, et al. Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. J Gynecol Oncol. 2009;20:101\u20136.","journal-title":"J Gynecol Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00673-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-020-00673-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00673-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T19:19:50Z","timestamp":1723058390000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-020-00673-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["673"],"URL":"https:\/\/doi.org\/10.1186\/s13048-020-00673-0","relation":{},"ISSN":["1757-2215"],"issn-type":[{"type":"electronic","value":"1757-2215"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"18 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the institutional review board of Jiangsu Cancer Hospital, Nanjing Medical University, China. The informed consent requirement was waived. The committee\u2019s reference number was Jiangsu Cancer Hospital\u2019s Ethical Committee 2016-05-01.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}